Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGC Pharma, Inc. (NYSE American: IGC) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing a structured view of its regulatory and corporate history. As a Maryland-incorporated, clinical-stage biotechnology company focused on Alzheimer's disease, pharmaceutical cannabinoids, and AI-driven research, IGC Pharma uses SEC filings to report material events, capital transactions, governance actions, and financial reporting changes.
Investors reviewing IGC Pharma’s filings will find multiple Form 8-K current reports detailing key developments. Recent 8-Ks describe a registered direct offering under an effective Form S-3 shelf registration statement, including a Subscription Agreement for the sale of common stock and the intended use of proceeds for working capital and clinical development programs. Other 8-Ks outline the completion of a Sale of Assets and Manufacturing Agreement through the company’s Holi Hemp LLC subsidiary, documenting the disposition of certain equipment, inventory, and operating assets of a Vancouver, Washington facility and the associated preferential supply rights and contingent consideration.
Additional 8-K filings and the DEF 14A proxy statement provide information on corporate governance and capital structure. These documents cover stockholder approval to increase authorized common stock from 150,000,000 to 600,000,000 shares, amendments to the Articles of Incorporation to implement that increase, and the election of directors and ratification of the independent registered public accounting firm. Another 8-K reports a change in fiscal year-end from March 31 to December 31 and the plan to file a transition report on Form 10-K for the nine-month period from April 1, 2025, through December 31, 2025.
Through Stock Titan, users can access IGC Pharma’s 10-K, 10-Q, 8-K, and proxy materials as they appear on EDGAR, along with AI-powered summaries that highlight the main points of lengthy documents. These summaries help explain complex topics such as equity offerings under a shelf registration, asset sale terms, changes in authorized share capital, or fiscal year transitions. The filings page is also the place to monitor exhibits such as material contracts, legal opinions, and pro forma financial information referenced in 8-Ks.
For those tracking IGC Pharma’s stock, this page offers a way to review how the company reports on its clinical-stage operations, capital planning, governance decisions, and other material events through official SEC channels, with AI tools available to make dense regulatory text more accessible.
IGC Pharma's CEO and director Ram Mukunda reported indirect transactions involving his spouse's holdings. On February 3, 2026, his spouse acquired 50,000 shares of common stock at $0.0 per share, bringing indirectly held common stock to 860,752 shares.
On the same date, the spouse was granted 16,667 restricted stock units that vest immediately and 66,666 restricted stock units that vest over time, both indirectly attributed "BY SPOUSE." Each restricted stock unit represents the right to receive one share of IGC common stock.
IGC Pharma director reports RSU conversion into common stock. On January 19, 2026, director Richard K. Prins exercised 100,000 restricted stock units, which were granted on March 13, 2024 and vest when specific board-approved milestones are achieved. Each unit represents the right to receive one share of IGC common stock, and the transaction was reported at an exercise price of $0.0 per unit. Following this transaction, Prins directly holds 1,371,251 shares of common stock and 50,000 restricted stock units.
IGC Pharma, Inc. entered into a Subscription Agreement for a registered direct offering of 779,997 shares of common stock at
IGC Pharma, Inc. is offering 779,997 shares of common stock at $0.30 per share in a direct registered offering without an underwriter or placement agent. The company expects gross proceeds of approximately $234,000 before estimated offering expenses of about $2,500.
Shares outstanding were 95,038,026 before the offering and are expected to be 95,818,023 after it. IGC Pharma plans to use the net proceeds to fund clinical trials, AI capabilities, research and development, facilities, marketing, investments in various asset classes, potential acquisitions aligned with its growth strategy, and general working capital. The company highlights significant risks, including broad discretion over use of proceeds and potential pressure on its stock price from freely tradable shares issued in this offering.
IGC Pharma, Inc. is changing its fiscal year-end from March 31 to December 31, with the change effective on December 31, 2025. This adjustment aligns the company’s financial reporting with the standard calendar year, which can make its results easier to compare with many other public companies. To bridge the gap between the old and new year-end, IGC plans to file a transition annual report covering a nine-month period from April 1, 2025 through December 31, 2025, giving investors a complete view of operations during the changeover period.
IGC Pharma, Inc. reported a charter amendment that significantly expands its capacity to issue common shares. Effective December 12, 2025, the company increased its authorized common stock from 150,000,000 to 600,000,000 shares, following approval by stockholders at the Annual Stockholders Meeting held on October 10, 2025. Total authorized shares of all classes rose from 150,000,000 to 601,000,000, including 1,000,000 shares of preferred stock that were unchanged.
The aggregate par value of all par value shares increased from $15,100.00 to $60,100.00, reflecting the larger number of authorized shares. The amendment was filed with and accepted by the Maryland State Department of Assessments and Taxation, and a copy of the Articles of Amendment is included as an exhibit to this report.
IGC Pharma, Inc. has filed an amended resale registration statement covering up to 978,235 shares of common stock, including 390,000 shares issuable upon exercise of stock options, for sale by existing security holders. The company itself is not selling any shares in this transaction and will not receive proceeds from these sales, though it will cover registration-related expenses.
The registered shares include 588,235 shares issued under a 2024 share purchase agreement with Moran Global Strategies, Inc. for $200,000 at $0.34 per share, and options granted to advisors for 390,000 shares at exercise prices around the current trading range. IGC Pharma is a clinical-stage company focused on using AI to develop treatments for Alzheimer’s disease, with lead candidate IGC-AD1 in a Phase 2 trial for agitation in Alzheimer’s dementia. The company notes that investing in its securities involves a high degree of risk and directs readers to detailed risk factors.
IGC Pharma, Inc. has filed a resale registration covering up to 978,235 shares of common stock, consisting of 588,235 outstanding shares and 390,000 shares issuable upon exercise of stock options. All shares may be sold from time to time by the selling stockholders, and the company will not sell shares or receive any proceeds from these resales. IGC will bear the registration expenses, while selling holders will bear their own selling costs.
The registered shares stem from equity issued or option grants under agreements with Moran Global Strategies, The Gutman Group, and advisor Professor Pablo Arbelaez. IGC’s common stock trades on the NYSE American under the symbol IGC, and the closing price on November 13, 2025 was $0.36 per share. IGC is a clinical-stage pharmaceutical company focused on AI-enabled therapies for Alzheimer’s disease, with lead candidate IGC-AD1 in a Phase 2 trial for agitation in Alzheimer’s patients. The prospectus emphasizes that investing in these securities involves a high degree of risk.
IGC Pharma filed its quarterly report for the period ended September 30, 2025. The company reported revenue of $191 thousand for the quarter and a net loss of $1.821 million. R&D expenses rose to $1.588 million as the Phase 2 trial of IGC‑AD1 advanced past the 50% enrollment mark.
Other income was $1.078 million, reflecting a gain from the sale of assets at the Vancouver, Washington facility. The transaction delivered approximately $2.7 million in consideration versus about $1.5 million of carrying value, and included preferential supply rights and a contingent 10% interest on a potential future sale by the buyer.
Cash and cash equivalents were $1.105 million at September 30, 2025, with working capital of $490 thousand. The company amended and extended its $12 million credit facility, reducing the annual facility fee and setting interest at the certificate of deposit rate plus a 1.2% margin. For the six months, revenue was $519 thousand and net cash used in operations was $3.497 million. Common shares outstanding were 91,959,112 as of September 30, 2025.